First-line treatment for patients with advanced squamous non–small cell lung cancer (NSCLC) typically involves chemotherapy combined with programmed cell death protein 1 (PD-1) inhibitors, but there remains a need to improve survival outcomes, especially for patients with low programmed death-ligand 1 (PD-L1) expression.
